Zacks Investment Research·Jun 19, 2026
Denali to Sell Priority Review Voucher for $195M Cash BoostDNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
Denali Therapeutics Inc.(DNLI)Earnings, Financials & Key Ratios
DNLI•NASDAQ
$25.74
Price updated Jul 6, 2026
AboutDenali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$541M-13.0%
- Net Income-$513M-21.2%
- EPS (Diluted)-2.97-15.6%
- ROE-45.69%-22.2%
DNLI Price & Volume
Denali Therapeutics Inc. (DNLI) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pipeline Costs Outpace Milestone Revenue Generation
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical milestone funding dependency
Key Thesis Takeaways
- Denali Therapeutics remains a high-risk, clinical-stage entity characterized by a total reliance on sporadic milestone payments rather than recurring commercial revenue.
- The company's persistent quarterly R&D expenditure of approximately $100 million continues to drive significant capital depletion, necessitating a cautious outlook regarding long-term operational sustainability.
- Investors should monitor the company's ability to secure further partnership funding, as the current cash position of $387.6 million remains vulnerable to the ongoing, high-burn clinical development model.
Verdict Logic
the company's reliance on non-recurring milestone payments and a persistent quarterly burn rate that necessitates a $23.1 million stock-based compensation expense to retain talent suggests significant long-term liquidity risk.
DNLI Growth Metrics
Denali Therapeutics Inc. (DNLI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-11.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.87%
Return on Capital
10 Years-28.63%
5 Years-32.55%
3 Years-35.84%
Last Year-47.91%
DNLI Recent Earnings
Denali Therapeutics Inc. (DNLI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.69+5.5%
$0.73
Rev
—
$3M
Q2 2026
May 5, 2026Metric
Actual
Est
EPS
$0.69+5.5%
$0.73
Rev
—
$3M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.73+2.7%
$0.75
Rev
—
$3M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.74+2.6%
$0.76
Rev
—
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.69vs $0.73+5.5% | —vs $3M |
| Q2 2026 | May 5, 2026 | $0.69vs $0.73+5.5% | —vs $3M |
| Q1 2026 | Feb 26, 2026 | $0.73vs $0.75+2.7% | —vs $3M |
| Q4 2025 | Nov 6, 2025 | $0.74vs $0.76+2.6% | —vs $3M |
Based on last 12 quarters of dataView full earnings history →
Latest DNLI News
Recent stock market news and headlines for Denali Therapeutics Inc. (DNLI)
GlobeNewsWire·Jun 18, 2026
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 MillionSOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. The U.S. Food and Drug Administration (FDA) awarded the PRV to Denali following accelerated approval of the enzyme replacement therapy AVLAYAH™ (tividenofusp alfa-eknm) for the treatment of Hunter syndrome (mucopolysaccharidosis type II; MPS II) in March 2026. AVLAYAH is the first FDA-approved medicine in an emerging class of biotherapeutics designed to cross the blood-brain barrier via transferrin receptor (TfR)-mediated transport.
Peers Comparison
Key metrics vs top competitors for Denali Therapeutics Inc. (DNLI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.74 | $4.09B | -8.67 | — | — | -45.69% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $8.45 | $545.2M | -6.60 | -0.3% | -247.54% | -44.39% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $131.50 | $8.46B | -64.15 | -89.41% | -648.27% | -17.76% | — |
Compare DNLI vs Peers
Denali Therapeutics Inc. (DNLI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DNLI SEC Filings & Documents
Denali Therapeutics Inc. (DNLI) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 3, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when DNLI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DNLI Frequently Asked Questions
Denali Therapeutics Inc. (DNLI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is DNLI profitable?
Denali Therapeutics Inc. (DNLI) reported a net loss of $508.0M for fiscal year 2025.
Dividend & Returns
What is DNLI's return on equity?
Denali Therapeutics Inc. (DNLI) has a return on equity (ROE) of -45.7%. Negative ROE indicates the company is unprofitable.
What is Denali Therapeutics Inc.'s free cash flow?
Denali Therapeutics Inc. (DNLI) had negative free cash flow of $419.2M in fiscal year 2025, likely due to heavy capital investments.